[Clinical efficacy of two-route chemotherapy with CDDP and STS in patients with peritonitis carcinomatosa].
Two-route chemotherapy of cisdiamminedichloroplatinum (CDDP) and sodium thiosulfate (STS) was performed in 32 patients with peritonitis carcinomatosa, originated from 21 gastric cancers, 4 colorectal cancers, 3 pancreatic cancers, 2 leiomyosarcomas of small intestine, one ovarian cancer and one bile duct cancer. CDDP was administered into the peritoneal cavity at the dose of 150 mg while STS was injected i.v., at the dose of 20 g to inactivate CDDP in peripheral blood. Out of 13 patients with malignant ascites, ascites disappeared completely in 3 cases and markedly decreased in 2 cases, and the efficacy rate was 38.5%. Five out of 32 registered patients with peritoneal disseminated tumors were evaluated. One complete response (CR), 1 partial response (PR), 2 with no change (NC) and 1 case of progressive disease (PD), were observed. The efficacy rate was 40%. The one-year and two-year cumulative survival rate was 18.2% and 13.7%, respectively. Nausea and vomiting were observed as side effects in about half of the patients, but these symptoms were mild and improved in a few days. These results indicate that this method is a useful therapy for peritonitis carcinomatosa.
First Dept. of Surgery, Medical College of Oita.
A
A
Kuwahara
T
T
Saito
K
K
Nakashima
Y
Y
Shigemitsu
E
E
Hirao
M
M
Kobayashi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000931:Antidotes / Q000008:administration & dosage* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000401:mortality; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D012074:Remission Induction; D013885:Thiosulfates / Q000008:administration & dosage* / Q000627:therapeutic use
D000931:Antidotes; D013885:Thiosulfates; C017717:sodium thiosulfate; D002945:Cisplatin